[ad_1]
SANTA MONICA, Calif. – (BUSINESS WIRE) – December 4, 2018 – Sixgill, LLC, the leader of data sensors services for Internet resources of Tutto (IoE), announced that Litmus Health will adopt Sixgill Integrity to provide blockchain accuracy and consistency of data for its clinical data science platform. The combination of Sixgill's data integrity and Litmus data expertise will provide a powerful solution for the processing and analysis of data from safe clinical trials .
The power and flexibility of the Sixgill-Litmus solution will allow the collection of sensor data, storage and chronological and real-time analysis based on an absolute security of the authenticity of the clinical data chain. With Sixgill Integrity, the authenticity of the data is guaranteed, the accuracy of the process is maintained and the clinical truth is guaranteed. Integrated with the Litmus clinical data platform, Sixgill Integrity will allow:
Saving of the truthfulness of the data
Authenticity of the validated device
Continuous regulatory level audit trails for physicians
Automatic and almost real-time alerts of any data compromise
A device-independent and ledger-based solution, Sixgill Integrity was designed from the ground up to address the fundamental need for a real-time end-to-end sensor data authenticity system. With Integrity, the Litmus platform will provide clinicians with the certainty that the data transmitted, the data transmitted, the data ingested and the data applied are the same.
"Sixgill Integrity protects from the proven reality that the security of digital systems is an illusion, but the data is defensible," says Phil Ressler, CEO of Sixgill, LLC. "Healthcare data are particularly personal, vulnerable and regulated.The goal of our exciting work with Litmus Health is to provide unprecedented security, transparency and immutability to validate, protect and defend carefully collected and strictly controlled clinical data" .
Through the Sixgill-Litmus partnership, clinicians reliably comply with the 21 CFR Part 11 Title regulations when conducting clinical trials.
Part 11 of Title 21 of the Code of Federal Regulations sets US regulations on food and drugs for electronic records. Part 11 defines the criteria for electronic records and electronic signatures to be considered reliable, reliable and equivalent to paper records. Litmus customers who use electronic data Patient Reported Outcome (ePRO) data from wearable devices, smart devices and home sensors will benefit from new ways to save time and costs, such as:
Efficiency in having a consistent source of data quality and security
Permanent review, traceability and certainty of a regulatory level
Quality automation and simplified processes
A revolutionary on-chain / off-chain hybrid approach to blockchain-enabled integrity that protects privacy and enables large-scale real-time performance
Improved data security with tamperable and time-series verifiable registers and notification of changes almost in real time
"We know how pressing concerns are for the accuracy and consistency of data for our customers, which is why the Litmus platform has always offered a stack that emphasizes the traceability and transparency of data flows. of clinical trials With the implementation of Sixgill Integrity, we are pleased to offer clinicians and researchers continuous testing of their clinical data chain, "says Daphne Kis, CEO of Litmus Health. "This partnership with Sixgill will accelerate the take-up and integration of new endpoints by researchers, while strengthening the integrity of the data acquired during clinical trials and observational studies."
Through this new collaboration, Sixgill seeks to demonstrate that the immutability of real and reliable control is feasible for any data system, and Litmus seeks to demonstrate that federally regulated health data projects can meet or exceed the authenticity mandates of data.
The combined aggregation, analysis and data integrity solution for clinical trials will be fully tested and generally available in the first quarter of 2019.
About Sixgill
Sixgill creates universal sensor data automation services that enable organizations to govern IoE resources. Sixgill Sense ™ offers developers the ability to easily capture, analyze and act on any data generated by the sensor, at any speed or scale. Sense offers customers a single powerful platform for unifying sensor data management, process automation and analysis for all sensor-sensitive applications. Other Sixgill products provide blockchain-based sensor data integrity and extend the power of sensor data automation to the edge of a network. To learn more, visit Sixgill.com.
About Litmus Health
The health of Litmus is a ready-to-search infrastructure for real-life data. We help our clients understand the behavior of patients and the environment in more dimensions. We use real-life data collected at the point of experience from wearable devices, smart devices and home sensors to drive management and inform both new and traditional endpoints. We help our clients to describe the full value of their work in observational studies, therapeutic trials and post-market research. From small observational studies to large-scale registries, we help researchers fundamentally unlock new insights from remote and telemetric patient data. For more information, visit: litmushealth.com.
© 2018 Sixgill, LLC. All rights reserved. Trademarks and logos are the property of their respective owners.
View the source version on businesswire.com: https://www.businesswire.com/news/home/20181204005306/en/
CONTACT: Sixgill:
Daniel Kehrer
Sixgill, LLC
310.254.1970
[email protected] Health:
Katarina Brown
Jones-Dilworth, Inc.
713.498.3643
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: DATA TECHNOLOGY MANAGEMENT VENTURE CAPITAL INTERNET NETWORKS SAFETY HEALTH BIOTECHNOLOGY CLINICAL STUDIES PHARMACEUTICAL MOBILE / WIRELESS PROFESSIONAL SERVICES RESEARCH OTHER SCIENCES SCIENCE GENERAL HEALTH
SOURCE: Sixgill, LLC
Copyright Business Wire 2018.
PUB: 12/04/2018 08:00 AM / DISC: 12/04/2018 08:01 AM
http://www.businesswire.com/news/home/20181204005306/en
